ImageboxPittsburgh Life Sciences GreenhouseLeft ArrowRight ArrowClose ButtonCloseDotLocationMenuQuoteSearchFacebookgoogle PlusLinkedInTwitterYoutubeBiotech ToolsDiagnosticsHealthcare ITMedical DevicesTherapeutics
Pittsburgh Life Sciences Greenhouse
Menu
  • Entrepreneurs
    • Stories
  • Investors
  • Impact
  • Portfolio
  • Resource Hub
  • LifeX Programs
  • Home
  • About
    • What is PLSG?
    • People
  • News
  • Blog
  • Contact
Pittsburgh Life Sciences Greenhouse
  • Home
  • About
    • What is PLSG?
    • People
  • News
  • Blog
  • Contact
  • Entrepreneurs
    • Stories
  • Investors
  • Impact
  • Portfolio
  • Resource Hub
  • LifeX Programs
Blog

Category: Venture Capital Perspective

Venture Capitalist Perspectives in a COVID-19 World – Part 2 of 2

Posted on April 7, 2020 by Diana Cugliari

After an informative conference call with leading venture capitalists, sponsored by the National Venture Capital Association, I felt there were some great takeaways worth sharing. The overarching theme was how to respond to and manage startup challenges that are only now starting to emerge in the chilly economic climate of a COVID-19 world.

What are some of the Go-To-Market strategies startups might have to face and adapt to?

Investors want to know that you have sensors out in the market. They want to know that you are listening to the needs of potential clients who want to engage. Since conferences and large gatherings simply are not happening, you’re going to need to find a new way to the top of the sales funnel. You need to get comfortable using Zoom and other meeting software–get GOOD at it; these platforms are quickly becoming part of a new cross-industry standard.

How would I raise a round remotely? Can you build the founder/partner relationship without conventional face-to-face meetings? 

Actually, seasoned venture capitalists are anticipating a future of investing without meeting every founder in person. Remember that the trust of the venture capitalist will be earned over time. Make sure you know your domain, develop a reputation for demonstrating customer engagement, and zero in on how your product fits in with the current climate—after all, the focus is going to be on data.

What’s the strategy for a startup that’s not currently in the “need to have” category? 

If it’s something that’s nice to have, find your way to the customer that must have it. In this climate, both businesses and customers are going to tighten up and focus on higher value initiatives. Anticipating this truth is of the utmost importance. If the startup team is too lean, and it becomes obvious that this is not the time to go to market, venture capitalists are going to take a pass.

Is it worth it to narrow the pitch to perceived value strictly in the shadow of COVID-19? Or should we continue chasing the big vision? 

The focus today is on keeping the company alive during a time of crisis, while continuing to nurture long-term strategies and the “big picture” for future growth. Though right now, today, we’re narrowing our vision to that “one feature” for that specific customer, we’re aware that certain sectors are going to be especially hard-hit. If you’re gunning for that “hard-hit” market, you need to either redirect or hit pause and hunker down. Remember: venture capitalists prefer situational awareness, so you’d better figure out where and how the company is currently positioned.

Are there other ways to make progress right now, other than selling to customers? 

Tons of progress can be made. Get out and meet with potential customers, develop a deeper understanding of their needs; where are the gaps? Are you still aligned with your people? Is your mission clear and well-communicated? Repurpose your time for product development so when the thaw comes, you have something special to share. Consider starting a funding round: This could be a prime opportunity to start a seed stage and get a company going. After all, it’s not likely to be a crowded competitive field vying for those same dollars.

Are there other ways to add value to your community when you’re a membership product?

To reiterate one of the most important points from earlier in the discussion: Listen to the needs of your current customers, and service them to the best of your ability. Become of source of assistance, information, and added value to your customer. Also, consider whether there is a solution you can provide to a need that is not usually handled by your product; diversification is almost always possible.

Posted in Uncategorized, Venture Capital PerspectiveLeave a comment

Venture Capitalist Perspectives in a COVID-19 World – Part 1 of 2

Posted on April 7, 2020 by Diana Cugliari

After an informative conference call with leading venture capitalists, sponsored by the National Venture Capital Association, I felt there were some great takeaways worth sharing. The overarching theme was how to respond to and manage startup challenges that are only now starting to emerge in the chilly economic climate of a COVID-19 world.

So, is anyone still investing? 

The answer is, generally, yes. On a macro level, venture capitalists are looking carefully at businesses in the early stages, where they may be seeking funding for early product development, for example. As companies move into later stages of growth, uncertainty starts to hamper their ability to make decisions—particularly during a crisis like the one at hand–so they are less attractive to investors.

What are the secrets to presenting well to venture capitalists in a time of virtual meetings only? 

Everyone needs to be using video for presentations, rather than hiding behind voice-only communication. The visual aspect means the meetings will take longer, but there is no overemphasizing the importance of the visual component in terms of making an impact through clear communication of ideas, potentially enabling a connection on a deeper level. Brevity and accuracy become paramount; and keeping details, content, and data tight will help to streamline initial presentations—get to the point quickly, and make the point clearly. Also, consider building relationships with shorter meetings with specific purpose(s). Follow-up sessions can often be kept to 30-45 minutes with each session building on the last.

What makes a pitch more attractive to venture capitalists during a downturn in the economy? 

Often, they (VCs) are looking for signs of life in troubled times. They want to know that you’re still engaging your customers and moving your product; that you’ve found the pockets of opportunity for your product to solve a key problem and prove that you’re still viable in this environment (i.e., could you diversify and/or move part of the business online?).

What are the most important data points for a startup to show potential investors, to prove they’re on point?

In short, customer retention and customer expansion are most attractive; clarity in financial planning and evidence that expenses are being brought under close control are also of great interest. Most importantly, under our new collective reality, show how you are going to retain control of the company’s destiny.

What else are startups to do differently now, than they did in the pre-COVID world? 

Primarily:  Make it your top priority to ensure your people are safe and healthy. Next, look at your existing customer….take great care of your existing customers. Modify your processes to generate goodwill among your clients and retain them through the hard times—anything you’re building has to be for them. Another central idea is to pull back on your expenses and do your best to “make do” with the resources at hand, erring, of course, on the side of caution and conservation, and putting the people and public health first.

Posted in Uncategorized, Venture Capital PerspectiveLeave a comment

Life Sciences Equals Economic Development

Posted on May 26, 2017 by Jim Jordan

Life Sciences drives economies, and for western PA it is one of our best contributors to economic development in the form of generating wealth and jobs. Just look at the math.

The term “life sciences” can include biotechnology, pharmaceutical, diagnostic, medical devices, and health care IT products – which make up approximately 40% of health care spending. And our nation’s health care system is projected to be $3.2 trillion by the end of the year. When you do the math, that’s $1.3 trillion in life sciences.  And that’s just the U.S.

In short, success in the life sciences is necessary for prosperity in a region, state, or nation.  We’re not talking about a subjective observation.  This statement comes via cold, irrefutable, objective calculations.  The economic impact of the life sciences industry is simply too big to ignore and too important not to invest in heavily.

Our local universities attract nearly $1 billion of federal funding each year to the region. That means if we were a state, the economic impact of western Pennsylvania’s federal funding for life sciences research alone would rank us among the top 12 states in the country.  That sounds big, and it is.

Lastly, the PLSG and its central role in fostering and advancing the life sciences in this region would not be in possible without foundation support.  Funding from regional foundations can be directly linked to an annual increase in Pittsburgh-area life sciences startups from three companies in 2002 to more than 12 today.  While we always would like to see more funding to support the innovation coming from our universities and entrepreneurs, the fact remains that our local foundations have been invaluable in moving the needle higher.

A high level of cooperation among investors, foundations, university researchers and technology transfer offices, local entrepreneurs, and organizations like PLSG is essential for success.  We must all focus on the same result – to generate economic prosperity, increased jobs, and a higher quality of life for our families, all through a stronger, more vibrant, and ever-expanding life sciences presence across this region.

Posted in PLSG News, Business Development, Health IT, Venture Capital Perspective, Medical Devices, Diagnostics, Therapeutics, Biotechnology Tools, Capital Investment Programs, Investment Growth Programs

Positioning Life Sciences Companies for Accurate Valuation and Strong Exits

Posted on April 13, 2015 by Jim Jordan

Click here to view slides.

Posted in Business Development, Venture Capital Perspective

Categories

  • PLSG Reminder
  • Under 40 Underserved Advisory Board
  • Uncategorized
  • PLSG News
  • Business Development
  • Health IT
  • Venture Capital Perspective
  • Words of Wisdom
  • Concentrations
  • Medical Devices
  • Diagnostics
  • Portfolio Companies
  • Therapeutics
  • Biotechnology Tools
  • Capital Investment Programs
  • Investment Growth Programs

Archives

Tags

  • Nanomedicine
  • Community
  • Development
  • Life Sciences
  • Entrepreneur

Contact

PO Box 42363
Pittsburgh, PA 15203

  • P: 412.201.7370
  • Email: info@plsg.com

Connect

© 2023 Pittsburgh Life Sciences Greenhouse. All rights reserved.

Website by Imagebox